Skip to main content

Table 1 Characteristics of studies of IL-6 rs1800795 polymorphism and T2DM and T1DM risk included in our meta-analysis

From: IL-6 gene rs1800795 polymorphism and diabetes mellitus: a comprehensive analysis involving 42,150 participants from a meta-analysis

Author Year Country Ethnicity Type Case Control SOC Cases Controls HWE Genotype NOS
CC CG GG CC CG GG
Campos 2019 Brasil Mixed T1DM 141 150 HB 9 69 63 7 68 75 0.084 PCR–RFLP 6
Mysliwiec 2008 Poland Caucasian T1DM 200 172 HB 59 105 36 43 75 54 0.103 PCR–RFLP 8
Siekiera 2002 Poland Caucasian T1DM 36 36 HB 5 24 7 12 18 6 0.684 PCR-SSP 6
Ururahy 2015 Brazil Mixed T1DM 120 152 HB 9 41 70 4 45 103 0.727 TaqMan 8
Settin 2009 Egypt African T1DM 50 98 PB 9 38 3 6 87 5  < 0.05 PCR-SSP 7
Javor 2010 Slovakia Caucasian T1DM 151 140 PB 31 85 35 21 66 53 0.951 PCR-SSP 7
Cooper 2007 USA Caucasian T1DM 8852 7785 PB 1612 4312 2928 1515 3814 2456 0.619 Taqman 7
Jahromi 2000 England Caucasian T1DM 257 120 PB 32 95 130 29 51 40 0.118 sequence 7
Tsiavou 2004 Greece Caucasian T1DM 31 39 PB 3 11 17 3 11 25 0.281 PCR-SSP 8
Mysliwska 2009 Poland Caucasian T1DM 210 170 PB 69 110 31 51 68 51  < 0.05 PCR–RFLP 8
Perez-Bravo 2011 Chile Mixed T1DM 145 103 PB 6 49 90 1 27 75 0.396 PCR–RFLP 7
Mukhopadhyaya 2010 India Asian T2DM 40 40 PB 6 11 23 15 13 12 0.029 PCR–RFLP 8
Hamid 2005 Denmark Caucasian T2DM 1389 4401 PB 328 659 402 1022 2133 1246 0.062 MALDI-TOF 9
Plataki 2018 Greece Caucasian T2DM 144 180 HB 12 64 68 12 54 114 0.119 PCR–RFLP 6
Vozarova 2003 Spain Caucasian T2DM 211 118 PB 17 110 84 19 65 34 0.193 PCR–RFLP 8
Buraczynska 2016 Poland Caucasian T2DM 1090 612 PB 240 534 316 129 288 195 0.237 sequence 9
Chen 2002 China Asian T2DM 196 130 HB 40 84 72 42 58 30 0.254 PCR–RFLP 7
Tsiavou 2004 Greece Caucasian T2DM 31 39 HB 3 11 17 3 11 25 0.281 PCR–SSP 6
Eze 2016 Switzerland Caucasian T2DM 286 5560 HB 40 135 111 865 2614 2081 0.352 Taqman 7
Bouhaha 2010 Tunisia African T2DM 169 281 PB 4 40 125 7 64 210 0.428 Sequencing 8
Ghavimi 2016 Iran Asian T2DM 120 120 HB 18 62 40 27 64 29 0.463 PCR–RFLP 7
Fathy 2018 Kuwait Asian T2DM 50 42 HB 1 13 36 2 11 29 0.487 TaqMan 8
Lara-Gómez 2019 Mexico Mixed T2DM 31 30 HB 1 11 19 0 5 25 0.618 Sequencing 7
Dhamodharan 2015 India Asian T2DM 139 106 HB 1 46 92 12 44 50 0.626 PCR–RFLP 7
Danielsson 2005 Sweden Caucasian T2DM 20 20 HB 6 12 2 6 9 5 0.662 Sequencing 7
Vozarova 2003 Spain Caucasian T2DM 143 145 PB 0 1 142 0 9 136 0.699 PCR–RFLP 9
Neelofar 2017 India Asian T2DM 50 50 HB 3 19 28 3 20 27 0.78 sequence 7
Kavitha 2016 India Asian T2DM 30 30 HB 0 0 30 0 1 29 0.926 PCR–RFLP 6
Kong 2010 China Asian T2DM 107 121 HB 0 2 105 0 2 119 0.927 PCR-SSP 6
Zhang 2011 China Asian T2DM 512 483 HB 0 2 510 0 1 482 0.982 PCR–RFLP 7
Saxena 2014 India Asian T2DM 213 145 HB 4 46 163 19 21 105  < 0.05 PCR–RFLP 6
Xiao 2009 China Asian T2DM 85 132 HB 0 0 85 0 0 132  < 0.05 PCR–RFLP 7
Nadeem 2017 Pakistan Asian T2DM 539 250 HB 37 267 235 48 74 128  < 0.05 PCR–RFLP 6
Karadeniz 2014 Turkey Caucasian T2DM 86 340 HB 6 27 53 26 171 143  < 0.05 PCR–RFLP 6
Erdogan 2017 Turkey Caucasian T2DM 35 119 HB 1 16 18 16 79 24  < 0.05 PCR–RFLP 8
Helaly 2013 Egypt African T2DM 69 98 PB 18 49 2 6 87 5  < 0.05 an allele–specific PCR 8
Mohlig 2004 Germany Caucasian T2DM 188 376 PB 32 103 53 71 208 97  < 0.05 SNuPE 8
  1. HB hospital-based; PB population-based; SOC source of control; PCR–RFLP polymerase chain reaction followed by restriction fragment length polymorphism; PCR-SSP polymerase chain reaction followed with sequence specific primers; MALDI-TOF a chip-based matrix-assisted laser-desorption/ionization time-of-flight; HWE Hardy–Weinberg equilibrium of control group; NOS Newcastle–Ottawa Scale